The prognostic value of plasma fibrinogen level in patients with acute myeloid leukemia: a systematic review and meta-analysis

References

• Miyawaki S. JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML). Int J Hematol. 2017;106(3):310–325.
   PubMed Web of Science ®Google Scholar
• Yan B, Chen Q, Xu J, et al. Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia. Leukemia. 2020. DOI:10.1038/s41375-020-0710-7
   Web of Science ®Google Scholar
• Grimwade D, on behalf of the National Cancer Research Institute Adult Leukaemia Working Group, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365.
   PubMed Web of Science ®Google Scholar
• Tennent GA, Brennan SO, Stangou AJ, et al. Human plasma fibrinogen is synthesized in the liver. Blood. 2007;109(5):1971–1974.
   PubMed Web of Science ®Google Scholar
• Wada H, Mori Y, Okabayashi K, et al. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. Am J Hematol. 2003;72(1):1–7.
   PubMed Web of Science ®Google Scholar
• Hou W, Zhang Y, Jin B, et al. Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone. Blood Cells Mol Dis. 2019; 79:102351.
   PubMed Web of Science ®Google Scholar
• Jackson K, Mollee P, Morris K, et al. Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit. Leuk Lymphoma. 2014;55(1):97–104.
   PubMed Web of Science ®Google Scholar
• Mantha S, Goldman DA, Devlin SM, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017;129(13):1763–1767.
   PubMed Web of Science ®Google Scholar
• Weltermann A, Pabinger I, Geissler K, et al. Hypofibrinogenemia in non-M3 acute myeloid leukemia. Incidence, clinical and laboratory characteristics and prognosis. Leukemia. 1998;12(8):1182–1186.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16.
   PubMed Web of Science ®Google Scholar
• Schellongowski P, Staudinger T, Kundi M, et al. Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience. Haematologica. 2011;96(2):231–237.
   PubMed Web of Science ®Google Scholar
• Berger MD, Heini AD, Seipel K, et al. Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia. Hematol Oncol. 2017;35(4):789–796.
   PubMed Web of Science ®Google Scholar
• Teke HU, Davutoglu NO, Gunduz E, et al. Prognostic factors, survival analysis and cytogenetic outcomes in adult patients with acute myeloid leukemia: a single center results. UHOD. 2017;27(3):150–160.
   Google Scholar
• Matarraz S, Leoz P, Fernández C, et al. Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy. Mod Pathol. 2018;31(8):1318–1331.
   PubMed Web of Science ®Google Scholar
• Dai K, Zhang Q, Li Y, et al. Plasma fibrinogen levels correlate with prognosis and treatment outcome in patients with non-M3 acute myeloid leukemia. Leuk Lymphoma. 2019;60(6):1503–1511.
   PubMed Web of Science ®Google Scholar
• Jin B, Zhang Y, Hou W, et al. Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide. J Cancer Res Clin Oncol. 2020;146(2):485–492.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15):1021–1028.
   PubMed Web of Science ®Google Scholar
• Iland H, for the Australasian Leukaemia and Lymphoma Group, Bradstock K, Seymour J, et al. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica. 2012;97(2):227–234.
   PubMed Web of Science ®Google Scholar
• Hou J, Wang S, Zhang Y, et al. Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide. Ann Hematol. 2017;96(12):2005–2013.
   PubMed Web of Science ®Google Scholar
• Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a nonrandomised phase 2 trial. Lancet Haematol. 2015;2(9):e357–366.
   PubMed Web of Science ®Google Scholar
• Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116(19):3751–3757.
   PubMed Web of Science ®Google Scholar
• Coutre SE, Othus M, Powell B, et al. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol. 2014;165(4):497–503.
   PubMed Web of Science ®Google Scholar
• Herrick S, Blanc-Brude O, Gray AC, et al. Fibrinogen. Int J Biochem Cell Biol. 1999;31(7):741–746.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Kikuchi E, Matsumoto K, et al. Prognostic value of plasma fibrinogen levels in patients with localized upper tract urothelial carcinoma. BJU Int. 2013;111(6):857–864.
   PubMed Web of Science ®Google Scholar
• Lawrence SO, Simpson-Haidaris PJ. Regulated de novo biosynthesis of fibrinogen in extrahepatic epithelial cells in response to inflammation. Thromb Haemost. 2004;92(2):234–243.
   PubMed Web of Science ®Google Scholar
• Heini AD, Hugo R, Berger MD, et al. Simple acute phase protein score to predict long-term survival in patients with acute myeloid leukemia. Hematol Oncol. 2020;38(1):74–81.
   PubMed Web of Science ®Google Scholar
• Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest. 2019;129(1):12–23.
   PubMed Web of Science ®Google Scholar
• Zheng S, Shen J, Jiao Y, et al. Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity. Cancer Sci. 2009;100(5):859–865.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899.
   PubMed Web of Science ®Google Scholar
• Sahni A, Simpson-Haidaris PJ, Sahni SK, et al. Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2). J Thromb Haemost. 2008;6(1):176–183.
   PubMed Web of Science ®Google Scholar
• Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96(10):3302–3309.
   PubMed Web of Science ®Google Scholar
• Nagy JA, Morgan ES, Herzberg KT, et al. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res. 1995;55(2):376–385.
   PubMed Web of Science ®Google Scholar
• Ciftciler R, Haznedaroglu IC, Aksu S, et al. The factors affecting early death in newly diagnosed APL patients. Open Med (Wars)). 2019;14:647–652.
   PubMedGoogle Scholar
• Iland HJ, Australasian Leukaemia and Lymphoma Group, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120(8):1570–1580; quiz 1752.
   PubMed Web of Science ®Google Scholar
• Mitrovic M, Suvajdzic N, Bogdanovic A, et al. International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥ 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia. Med Oncol. 2013;30(1):478.
   PubMed Web of Science ®Google Scholar
• Yanada M, Matsushita T, Asou N, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol. 2007;78(3):213–219.
   PubMed Web of Science ®Google Scholar
• Zou YX, Qiao J, Zhu HY, et al. Albumin-to-fibrinogen ratio as an independent prognostic parameter in untreated chronic lymphocytic leukemia: a retrospective study of 191 cases. Cancer Res Treat. 2019;51(2):664–671.
   PubMed Web of Science ®Google Scholar